<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">cid</journal-id><journal-title-group><journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title></journal-title-group><issn pub-type="ppub">1058-4838</issn><issn pub-type="epub">1537-6591</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7499532</article-id><article-id pub-id-type="pmid">32857836</article-id><article-id pub-id-type="doi">10.1093/cid/ciaa1290</article-id><article-id pub-id-type="publisher-id">ciaa1290</article-id><article-categories><subj-group subj-group-type="heading"><subject>Viewpoints</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00290</subject></subj-group></article-categories><title-group><article-title>Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Levine</surname><given-names>Myron M</given-names></name><degrees>MD, DTPH</degrees><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="corresp" rid="c1"/><!--<email>mlevine@som.umaryland.edu</email>--></contrib><contrib contrib-type="author"><name><surname>Abdullah</surname><given-names>Salim</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Arabi</surname><given-names>Yaseen M</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Darko</surname><given-names>Delese Mimi</given-names></name><degrees>B Pharm</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Durbin</surname><given-names>Anna P</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Estrada</surname><given-names>Vicente</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Jamrozik</surname><given-names>Euzebiusz</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Kremsner</surname><given-names>Peter G</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0008">8</xref><xref ref-type="aff" rid="AF0009">9</xref></contrib><contrib contrib-type="author"><name><surname>Lagos</surname><given-names>Rosanna</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0010">10</xref></contrib><contrib contrib-type="author"><name><surname>Pitisuttithum</surname><given-names>Punnee</given-names></name><degrees>MBBS, DTM&#x00026;H, FRCPT</degrees><xref ref-type="aff" rid="AF0011">11</xref></contrib><contrib contrib-type="author"><name><surname>Plotkin</surname><given-names>Stanley A</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0012">12</xref></contrib><contrib contrib-type="author"><name><surname>Sauerwein</surname><given-names>Robert</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0013">13</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Sheng-Li</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0014">14</xref></contrib><contrib contrib-type="author"><name><surname>Sommerfelt</surname><given-names>Halvor</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0015">15</xref></contrib><contrib contrib-type="author"><name><surname>Subbarao</surname><given-names>Kanta</given-names></name><degrees>MBBS</degrees><xref ref-type="aff" rid="AF0016">16</xref></contrib><contrib contrib-type="author"><name><surname>Treanor</surname><given-names>John J</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0017">17</xref></contrib><contrib contrib-type="author"><name><surname>Vrati</surname><given-names>Sudhanshu</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0018">18</xref></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>Deborah</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0019">19</xref></contrib><contrib contrib-type="author"><name><surname>Balasingam</surname><given-names>Shobana</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AF0020">20</xref></contrib><contrib contrib-type="author"><name><surname>Weller</surname><given-names>Charlie</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0021">21</xref></contrib><contrib contrib-type="author"><name><surname>Aguilar</surname><given-names>Anastazia Older</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0022">22</xref></contrib><contrib contrib-type="author"><name><surname>Cassetti</surname><given-names>M Cristina</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0023">23</xref></contrib><contrib contrib-type="author"><name><surname>Krause</surname><given-names>Philip R</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0024">24</xref></contrib><contrib contrib-type="author"><name><surname>Restrepo</surname><given-names>Ana Maria Henao</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0025">25</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>
<institution>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore</institution>, MD, <country country="US">USA</country></aff><aff id="AF0002"><label>2</label>
<institution>Ifakara Health Institute (IHI)</institution>, Ifakara, Tanzania</aff><aff id="AF0003"><label>3</label>
<institution>College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center</institution>, Riyadh, Kingdom of Saudi Arabia</aff><aff id="AF0004"><label>4</label>
<institution>CEO, FDA, Cantonments</institution>, Accra, Ghana</aff><aff id="AF0005"><label>5</label>
<institution>Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore</institution>, MD, <country country="US">USA</country></aff><aff id="AF0006"><label>6</label>
<institution>Medical School, Complutense University</institution>, Hospital Cl&#x000ed;nico San Carlos, Madrid, <country country="ES">Spain</country></aff><aff id="AF0007"><label>7</label>
<institution>Monash Bioethics Centre, Monash University, Victoria</institution>, <country country="AU">Australia</country></aff><aff id="AF0008"><label>8</label>
<institution>Institut f&#x000fc;r Tropenmedizin, Universit&#x000e4;tsklinikum T&#x000fc;bingen</institution>, <country country="DE">Germany</country></aff><aff id="AF0009"><label>9</label>
<institution>Centre de Recherches M&#x000e9;dicales de Lambar&#x000e9;n&#x000e9;</institution>, <country country="GA">Gabon</country></aff><aff id="AF0010"><label>10</label>
<institution>Centro para Vacunas en Desarrollo</institution>, Santiago, <country country="CL">Chile</country></aff><aff id="AF0011"><label>11</label>
<institution>Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University</institution>, Bangkok, <country country="TH">Thailand</country></aff><aff id="AF0012"><label>12</label>
<institution>Department of Pediatrics, University of Pennsylvania</institution>, Doylestown, PA, <country country="US">USA</country></aff><aff id="AF0013"><label>13</label>
<institution>Medical Parasitology Department, Radboud University</institution>, Nijmegen, <country country="NL">The Netherlands</country></aff><aff id="AF0014"><label>14</label>
<institution>Director Center for Emerging Infectious Diseases, Wuhan Institute of Virology</institution>, Wuhan, <country country="CN">China</country></aff><aff id="AF0015"><label>15</label>
<institution>Centre for Intervention Science in Maternal and Child Health, Department of Global Public Health and Primary Care, University of Bergen</institution>, Bergen, and Norwegian Institute of Public Health, Oslo, Norway</aff><aff id="AF0016"><label>16</label>
<institution>WHO Collaborating Centre for Reference and Research on Influenza and Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute</institution>, Melbourne, <country country="AU">Australia</country></aff><aff id="AF0017"><label>17</label>
<institution>Infectious Diseases Division, University of Rochester Medical Center</institution>, Rochester NY, <country country="US">USA</country></aff><aff id="AF0018"><label>18</label>
<institution>Regional Centre for Biotechnology</institution>, Faridabad, Haryana (NCR Delhi), <country country="IN">India</country></aff><aff id="AF0019"><label>19</label>
<institution>Vaccines Priority Area, Wellcome Trust</institution>, , London, <country country="GB">UK</country></aff><aff id="AF0020"><label>20</label>
<institution>Vaccines, Wellcome Trust</institution>, , London, <country country="GB">UK</country></aff><aff id="AF0021"><label>21</label>
<institution>Vaccines Programme, Wellcome Trust</institution>, , London, NW1 2BE, <country country="GB">UK</country></aff><aff id="AF0022"><label>22</label>
<institution>Global Health Discovery &#x00026; Translational Sciences</institution>, Bill &#x00026; Melinda Gates Foundation, Seattle, WA, USA</aff><aff id="AF0023"><label>23</label>
<institution>Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</institution>, Bethesda, MD</aff><aff id="AF0024"><label>24</label>
<institution>Office of Vaccines Research and Review, CEBR, FDA</institution>, Silver Spring, MD, USA, and Chair, WHO R&#x00026;D Blueprint COVID-19 Vaccines Working Group</aff><aff id="AF0025"><label>25</label>
<institution>Office of the Executive Director (WHE), WHO Health Emergencies Programme, World Health Organization</institution>, Geneva, <country country="CH">Switzerland</country></aff><author-notes><corresp id="c1">Corresponding author: Myron Levine, Email: <email>mlevine@som.umaryland.edu</email></corresp></author-notes><pub-date pub-type="epub" iso-8601-date="2020-08-28"><day>28</day><month>8</month><year>2020</year></pub-date><elocation-id>ciaa1290</elocation-id><history><date date-type="received"><day>26</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.</copyright-statement><copyright-year>2020</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="ciaa1290.pdf"/><abstract><title>Abstract</title><p>WHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2&#x02019;s potential to cause severe/fatal illness, its high transmissibility, and lack of a &#x0201c;rescue treatment&#x0201d; to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot <italic>per se</italic> be extrapolated to predict efficacy in elderly/high-risk adults.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>challenge model</kwd><kwd>experimental challenge</kwd><kwd>adult volunteers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>article-lifecycle</meta-name><meta-value>PAP</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>accepted-manuscript</meta-value></custom-meta></custom-meta-group></article-meta></front></article>